Regular ArticlePhase I Trial of Taxol as a Radiation Sensitizer with Cisplatin in Advanced Cervical Cancer
References (28)
Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma
Gynecol Oncol
(1993)- et al.
Taxol: A novel radiation sensitizer
Int J Radiat Oncol Biol Phys
(1992) - et al.
Taxol sensitizes human ovarian cancer cells to radiation
Gynecol Oncol
(1993) - et al.
Paclitaxel: a radiation sensitizer of human cervical cancer cells
Gynecol Oncol
(1995) - et al.
Radiation and taxol effects on synchronized human cervical cancer cell
Int J Radiat Oncol Biol Phys
(1994) - et al.
Paclitaxel is only a weak radiosensitizer of human cervical carcinoma cell lines
Gynecol Oncol
(1996) - et al.
Influence of surgical staging on the evaluation and treatment of patients with cervical carcinoma
Gynecol Oncol
(1986) - et al.
Murine intestinal crypt survival after combined taxol plus radiation exposure
Gynecol Oncol
(1996) - et al.
Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa
Int J Radiat Oncol Biol Phys
(1995) - et al.
Taxol stabilizes mictotubules in mouse fibroblast cells
Proc Natl Acad Sci U.S.A.
(1980)
Taxol: a novel investigational antimicrotubule agent
J Natl Cancer Inst
Phase II study of paclitaxel in metastatic melanoma
Cancer
Phase II trial of taxol, an active drug in metastatic breast cancer
J Natl Cancer Inst
Cited by (53)
Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial
2016, Gynecologic OncologyCitation Excerpt :However, 1 of the patients in the present study experienced a grade 4 cerebral hemorrhage 1.5 years after irradiation, which is unlikely to have any direct causal relationship with the study, suggesting that the late event rates between the studies may be considered comparable. Several clinical studies of CCRT with CDDP and PTX in the treatment of cervical cancer have been reported to date [10,11,15–18]. Chen et al. [15] and Pignata et al. [16] reported the efficacy of CCRT with CDDP and PTX with response rates of ≥ 90% in their phase I studies.
Quality of life (QOL) in women treated for gynecologic malignancies with radiation therapy: A literature review of patient - Reported outcomes
2014, Gynecologic OncologyCitation Excerpt :Pelvic radiation therapy has several known acute and long term toxicities. Acute treatment-related toxicities include dermatitis, mucositis, diarrhea, and dysuria, among others [1,2]. These side effects can generally be managed with skin creams, anti-diarrhea medications, and pain medications, and may resolve shortly after the completion of therapy.
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium
2013, Gynecologic OncologyCitation Excerpt :By comparison, Martinez et al. reported a 14% rate of chronic gastrointestinal toxic effects in patients treated with WAPI [7]. Our paclitaxel dose of 50 mg/m2 weekly, which we chose on the basis of published findings indicating that this dose is associated with minimal and manageable toxic effects [16–18], may have been too high for our relatively elderly patients (mean age, 63 years); a dose of 40 mg/m2 weekly might have been better tolerated. Another potential means of reducing bowel toxic effects, the use of IMRT, was not allowed in our study.
Maximum Tolerated Dose and Early Response - Results of a Phase I Trial of Paclitaxel and Cisplatin with Radiation Therapy in Carcinoma of the Cervix<sup>1</sup>
2009, Clinical OncologyCitation Excerpt :Phase I trials using paclitaxel and cisplatin once a week have shown that doses of 40–60 mg/m2/week of paclitaxel with 30–50 mg/m2/week of cisplatin were well tolerated. The most common toxicities described were neutropenia and diarrhoea [9–12]. The early response rate was 97.7% with a complete response rate of 84.9%.
A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: A gynecologic oncology group study
2009, Gynecologic OncologyCitation Excerpt :There had been one previous trial looking at the combination of paclitaxel and cisplatin with radiation therapy in cervical cancer. Chen, et al. reported on a phase I study of escalating doses of paclitaxel as a radiation sensitizer in combination with cisplatin [15]. The results demonstrated a well-tolerated dose range starting at 10 mg/m2 weekly and advancing to 50 mg/m2 weekly in combination with cisplatin 50 mg/m2 every three weeks.